CHUGAI PHARMACEUTICAL CO., LTD Toevoegen aan een lijst
|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 4.852 JPY | -0,16% |
|
-1,40% | -9,17% |
| 25/04 | Chugai Pharmaceutical's moederbedrijf Roche boekt lagere omzet in Q1; aandeel daalt 5% | MT |
| 24/04 | Chugai Pharmaceutical's winst licht gestegen in Q1 | MT |
Totale waarde
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Marktkapitalisatie 1 | 5.518.359 | 9.045.924 | 6.141.311 | 5.540.406 | 8.789.053 | 7.983.063 | - | - |
| Bedrijfswaarde 1 | 5.185.301 | 8.667.304 | 5.669.311 | 5.051.408 | 8.050.071 | 7.102.495 | 6.980.320 | 6.833.877 |
| K/w-verhouding | 35 x | 42,1 x | 20,3 x | 14,8 x | 27 x | 23,2 x | 21,7 x | 20,4 x |
| Dividendrendement | 1,39% | 1% | 2,03% | 2,32% | 1,5% | 1,74% | 1,84% | 1,89% |
| Marktkapitalisatie/omzet | 8,04 x | 11,5 x | 6,14 x | 4,4 x | 7,91 x | 7,31 x | 7,04 x | 6,78 x |
| Bedrijfswaarde/omzet | 7,56 x | 11 x | 5,67 x | 4,01 x | 7,24 x | 6,51 x | 6,15 x | 5,8 x |
| Bedrijfswaarde/EBITDA | 22,5 x | 26,1 x | 12,3 x | 8,93 x | 17,1 x | 14,4 x | 13,6 x | 12,9 x |
| Bedrijfswaarde/FCF | 41,5 x | 81,2 x | 35,3 x | 27,7 x | 21,6 x | 20,9 x | 21,7 x | 19,9 x |
| FCF Yield | 2,41% | 1,23% | 2,83% | 3,61% | 4,63% | 4,79% | 4,61% | 5,03% |
| Price to Book | 6,46 x | 9,23 x | 5,17 x | 3,89 x | 5,41 x | 4,42 x | 3,76 x | 3,34 x |
| Aantal aandelen (in duizenden) | 1.642.369 | 1.643.817 | 1.644.260 | 1.645.014 | 1.645.274 | 1.645.314 | - | - |
| Referentieprijs 2 | 3.360 | 5.503 | 3.735 | 3.368 | 5.342 | 4.852 | 4.852 | 4.852 |
| Datum van publicatie | 30-01-20 | 04-02-21 | 03-02-22 | 02-02-23 | 01-02-24 | - | - | - |
1JPY in Miljoen2JPY
Geschatte gegevens
Evolutie van de resultatenrekening (Jaargegevens)
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 686.184 | 786.900 | 999.800 | 1.259.946 | 1.111.367 | 1.091.346 | 1.134.578 | 1.177.952 |
| EBITDA 1 | 230.967 | 332.600 | 459.100 | 565.376 | 470.914 | 492.349 | 514.577 | 528.112 |
| Bedrijfsresultaat (EBIT) 1 | 210.597 | 301.200 | 421.900 | 533.309 | 439.174 | 467.911 | 499.004 | 529.915 |
| Operationele Marge | 30,69% | 38,28% | 42,2% | 42,33% | 39,52% | 42,87% | 43,98% | 44,99% |
| Resultaat voor belastingen (EBT) 1 | 207.893 | 298.200 | 419.400 | 531.166 | 443.821 | 471.033 | 503.963 | 535.490 |
| Nettowinst (verlies) 1 | 157.560 | 214.700 | 303.000 | 374.429 | 325.472 | 345.245 | 368.453 | 392.430 |
| Nettomarge | 22,96% | 27,28% | 30,31% | 29,72% | 29,29% | 31,63% | 32,47% | 33,31% |
| WPA 2 | 95,95 | 130,7 | 184,3 | 227,6 | 197,8 | 209,5 | 223,5 | 238,1 |
| Free Cash Flow 1 | 124.900 | 106.723 | 160.699 | 182.312 | 372.635 | 340.431 | 321.522 | 343.677 |
| FCF-marge | 18,2% | 13,56% | 16,07% | 14,47% | 33,53% | 31,19% | 28,34% | 29,18% |
| Kasstroomconversie (ebitda) | 54,08% | 32,09% | 35% | 32,25% | 79,13% | 69,14% | 62,48% | 65,08% |
| Kasstroomconversie (nettowinst) | 79,27% | 49,71% | 53,04% | 48,69% | 114,49% | 98,61% | 87,26% | 87,58% |
| Dividend per aandeel 2 | 46,67 | 55,00 | 76,00 | 78,00 | 80,00 | 84,46 | 89,31 | 91,50 |
| Datum van publicatie | 30-01-20 | 04-02-21 | 03-02-22 | 02-02-23 | 01-02-24 | - | - | - |
1JPY in Miljoen2JPY
Geschatte gegevens
Evolutie van de resultatenrekening (Kwartaalgegevens)
| Fiscaal tijdperk: december | 2019 S2 | 2020 S1 | 2021 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 S1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 365.899 | 368.120 | 390.229 | 287.264 | 322.300 | 360.554 | 235.600 | 596.200 | 225.300 | 438.446 | 312.240 | 267.417 | 579.657 | 257.898 | 273.812 | 236.900 | 277.386 | 521.000 | 275.285 | 295.945 | 259.000 | 545.000 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 107.900 | 128.800 | - | 121.000 | 120.300 | - | - |
| Bedrijfsresultaat (EBIT) 1 | 115.545 | 140.629 | 160.679 | 122.156 | 139.100 | 187.007 | 99.900 | 286.900 | 96.900 | 149.509 | 98.296 | 112.614 | 210.910 | 106.688 | 121.576 | 99.900 | 120.281 | 215.200 | 119.205 | 126.325 | 115.100 | 238.200 |
| Operationele Marge | 31,58% | 38,2% | 41,18% | 42,52% | 43,16% | 51,87% | 42,4% | 48,12% | 43,01% | 34,1% | 31,48% | 42,11% | 36,39% | 41,37% | 44,4% | 42,17% | 43,36% | 41,31% | 43,3% | 42,69% | 44,44% | 43,71% |
| Resultaat voor belastingen (EBT) 1 | 114.113 | 139.565 | 161.256 | 119.689 | 138.400 | 186.206 | 100.700 | 286.900 | 95.000 | 149.266 | 99.662 | 113.994 | 213.656 | 107.475 | 122.690 | 99.900 | 126.400 | 216.700 | 130.600 | 129.100 | 115.400 | 238.700 |
| Nettowinst (verlies) 1 | 88.306 | 102.293 | 118.137 | 86.017 | 98.800 | 131.775 | 72.400 | 204.200 | 67.800 | 102.429 | 73.500 | 83.193 | 156.693 | 77.573 | 91.206 | 74.400 | 89.295 | 157.450 | 89.681 | 91.632 | 85.900 | 175.700 |
| Nettomarge | 24,13% | 27,79% | 30,27% | 29,94% | 30,65% | 36,55% | 30,73% | 34,25% | 30,09% | 23,36% | 23,54% | 31,11% | 27,03% | 30,08% | 33,31% | 31,41% | 32,19% | 30,22% | 32,58% | 30,96% | 33,17% | 32,24% |
| WPA 2 | - | 62,26 | 71,86 | 52,31 | 60,11 | 80,14 | 44,00 | 124,1 | 41,21 | 62,29 | 44,68 | 50,57 | 95,25 | 47,15 | 55,43 | 45,22 | 52,88 | 96,50 | 54,37 | 59,93 | 52,20 | 106,8 |
| Dividend per aandeel | - | 25,00 | 30,00 | - | - | - | - | 38,00 | - | - | - | - | 40,00 | - | 40,00 | - | - | - | - | - | - | - |
| Datum van publicatie | 30-01-20 | 27-07-20 | 26-07-21 | 22-10-21 | 03-02-22 | 25-04-22 | 21-07-22 | 21-07-22 | 24-10-22 | 02-02-23 | 27-04-23 | 27-07-23 | 27-07-23 | 24-10-23 | 01-02-24 | 24-04-24 | - | - | - | - | - | - |
1JPY in Miljoen2JPY
Geschatte gegevens
Balans
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Nettoschuldpositie 1 | - | - | - | - | - | - | - | - |
| Nettokaspositie 1 | 333.058 | 378.620 | 472.000 | 488.998 | 738.982 | 880.569 | 1.002.743 | 1.149.187 |
| Hefboom (schuld/ebitda) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 124.900 | 106.723 | 160.699 | 182.312 | 372.635 | 340.431 | 321.522 | 343.677 |
| ROE (netto-inkomsten/eigen vermogen) | 19,6% | 23,4% | 28% | 28,7% | 21,3% | 20,1% | 18,6% | 17,4% |
| ROA (netto-inkomsten/totale activa) | 15,9% | 26% | 30,2% | 31,2% | 23,3% | 16,8% | 15,2% | 13,8% |
| Totale activa 1 | 989.232 | 826.007 | 1.002.158 | 1.201.341 | 1.394.192 | 2.050.962 | 2.417.668 | 2.847.826 |
| Nettoactief per aandeel 2 | 520,0 | 596,0 | 723,0 | 866,0 | 988,0 | 1.099 | 1.289 | 1.455 |
| Cashflow per aandeel 2 | 108,0 | 149,0 | 203,0 | 247,0 | 217,0 | 261,0 | 237,0 | 246,0 |
| Capex 1 | 53.009 | 57.040 | 65.969 | 61.800 | 71.948 | 66.072 | 67.548 | 68.635 |
| Capex/omzet | 7,73% | 7,25% | 6,6% | 4,9% | 6,47% | 6,05% | 5,95% | 5,83% |
| Datum van publicatie | 30-01-20 | 04-02-21 | 03-02-22 | 02-02-23 | 01-02-24 | - | - | - |
1JPY in Miljoen2JPY
Geschatte gegevens
WPA & Dividend
Historische koers/winstverhouding
Evolutie van de historische prestaties
Historische marktkapitalisatie/EBITDA
Trading rating
Beleggingsrating
ESG Refinitiv
A-
Verkoop
Koop
Gemiddeld advies
Accumuleren
Aantal analisten
14
Laatste slotkoers
4.852
JPY
Gemiddelde koersdoel
6.044
JPY
Spread / Gemiddelde doel
+24,56%
Herzieningen van WPA
| Vaira. 1 jan. | Kapi. | |
|---|---|---|
| -9,17% | 50,71 mld. | |
| +25,83% | 661 mld. | |
| +27,00% | 566 mld. | |
| -6,76% | 352 mld. | |
| +20,34% | 332 mld. | |
| +3,00% | 283 mld. | |
| +13,09% | 231 mld. | |
| +5,46% | 200 mld. | |
| -9,61% | 195 mld. | |
| -6,26% | 145 mld. |
- Beurs
- Aandelen
- Koers 4519
- Financiën Chugai Pharmaceutical Co., Ltd
